TABLE 1.
Number of past VL cases per period, where the cases were treated, and antileishmania drug received
| Time between VL treatment and November 2006 blood sampling (no. of subjects) | % (no.) of cases treated by facilitya: |
% (no.) of cases treated withd: |
% (no.) of cases positive bye: |
|||
|---|---|---|---|---|---|---|
| Governmentb | Private/NGOc | SSG | Amphotericin B | DAT | rK39 ELISA | |
| <1 yr (124) | 19.4 (24) | 80.6 (100) | 31.5 (39) | 61.3 (76) | 93.5 (116) | 86.3 (107) |
| 1-<5 yr (447) | 16.1 (72) | 83.7 (374) | 38.0 (170) | 55.9 (250) | 89.3 (399) | 68.2 (305) |
| 5-<10 yr (123) | 13.0 (16) | 87.0 (107) | 53.7 (66) | 45.5 (56) | 80.5 (99) | 57.7 (71) |
| 10-<15 yr (35) | 25.7 (9) | 74.3 (26) | 68.6 (24) | 31.4 (11) | 68.6 (24) | 42.9 (15) |
| ≥15 yr (51) | 29.4 (15) | 62.7 (32) | 84.3 (43) | 7.8 (4) | 52.9 (27) | 39.2 (20) |
a
Other sites and “unknown” not shown.
b
District Hospital, Medical College, and Community Health Centres.
c
Private hospitals or health centers and nongovernmental organizations (NGO; i.e., Kala Azar Medical Research Centre in Muzaffapur).
d
Other drugs (i.e., miltefosine) and “unknown” not shown. SSG, sodium stibogluconate.
e
Cutoff values: DAT, titer of 1:3,200; rK39 ELISA, 22% positivity.